Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)

China flag China · Delayed Price · Currency is CNY
68.16
+1.80 (2.71%)
Nov 12, 2024, 3:00 PM CST
38.71%
Market Cap 18.04B
Revenue (ttm) 488.45M
Net Income (ttm) -174.40M
Shares Out 264.71M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,866,748
Open 66.68
Previous Close 66.36
Day's Range 65.61 - 70.00
52-Week Range 33.20 - 79.99
Beta 0.62
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 867
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2023, Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s revenue was 386.44 million, an increase of 27.83% compared to the previous year's 302.31 million. Losses were -278.58 million, -39.08% less than in 2022.

Financial Statements

News

There is no news available yet.